IVA
Twin Vee Powercats, Inc.
NASDAQ · Healthcare · Biotechnology · FR
$2.98
+1.36%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 12.3M | 4.5M | 9.2M | 17.5M | 12.2M |
| Cost of Revenue | 2.8M | 2.8M | 3.9M | (23.0K) | 995.0K |
| Gross Profit | 9.4M | 1.5M | 9.2M | 17.5M | 17.1M |
| Operating Expenses | |||||
| R&D Expense | 177.2M | 83.6M | 90.9M | 110.0M | 60.5M |
| SG&A Expense | 85.7M | 53.9M | 17.1M | 15.6M | 15.5M |
| General & Admin Expense | 77.0M | 49.1M | 15.4M | 13.9M | 12.9M |
| Selling & Marketing Expense | 8.7M | 4.8M | 1.7M | 1.8M | 2.6M |
| Other Expenses | (2.1M) | (133.6K) | (1.2M) | (5.4M) | (1.8M) |
| Total Operating Expenses | 260.9M | 137.4M | 106.8M | 120.2M | 74.2M |
| Cost and Expenses | 263.7M | 137.4M | 106.8M | 120.2M | 75.2M |
| Operating Income (EBIT) | (246.6M) | (130.9M) | (97.6M) | (102.7M) | (57.1M) |
| Non-Operating | |||||
| Interest Income | 6.3M | 2.8M | 1.1M | 945.0K | 390.0K |
| Interest Expense | 60.3M | 32.3M | 12.2M | 5.2M | 707.0K |
| Net Interest Income | (54.0M) | (29.5M) | (11.1M) | (4.2M) | (317.0K) |
| Other Non-Op Income/Expense | (300.0M) | (211.4M) | (86.3M) | (7.1M) | 2.8M |
| Non-Operating Income (excl Interest) | 184.9M | — | 74.2M | 1.9M | 48.0K |
| EBT (Pre-Tax Income) | (546.7M) | (342.3M) | (183.9M) | (109.8M) | (54.3M) |
| Income Tax Expense | (2.0M) | 22.0K | 313.0K | 607.0K | (20.0K) |
| Bottom Line | |||||
| Net Income | (558.4M) | (340.2M) | (184.2M) | (110.4M) | (54.3M) |
| Earnings from Cont. Ops | (557.5M) | (354.1M) | (184.2M) | (110.4M) | (54.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (558.4M) | (340.2M) | (184.2M) | (110.4M) | (54.3M) |
| Per Share | |||||
| Basic EPS | ($4.76) | ($1.82) | ($3.54) | ($2.43) | ($1.31) |
| Diluted EPS | ($4.76) | ($1.82) | ($3.54) | ($2.43) | ($1.31) |
| Revenue Per Share | $0.04 | $0.02 | $0.18 | $0.39 | $0.29 |
| Shares | |||||
| Basic Shares Outstanding | 273.6M | 186.8M | 52.0M | 45.4M | 41.4M |
| Diluted Shares Outstanding | 273.6M | 186.8M | 52.0M | 45.4M | 41.4M |
| Profitability Metrics | |||||
| EBITDA | (432.0M) | (127.7M) | (166.5M) | (102.0M) | (55.5M) |
| D&A | 6.0M | 3.2M | 5.2M | 2.6M | 1.7M |
| EBIT | (437.7M) | (130.9M) | (171.7M) | (104.6M) | (57.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026